Morgan Stanley lowered the firm’s price target on Eli Lilly (LLY) to $1,124 from $1,146 and keeps an Overweight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Trump-Powered Medicare Setback Adds Bullish Impetus for Eli Lilly & Co (LLY) Stock
- Trump plans to announce ‘major’ tariff on pharmaceutical imports, Reuters says
- Trump Plans “Major Tariff on Pharmaceuticals” as Global Economies Crumble
- AMD downgraded, Dollar General upgraded: Wall Street’s top analyst calls
- Eli Lilly assumed with Buy from Neutral at Goldman Sachs